Sugi Predict

Sugi Predict / Compounds / SCHEMBL9056432

SCHEMBL9056432

SCHEMBL9056432

O=c1c(Br)coc2ccc(F)cc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 3/20 0.61
▸ KDM4E B2RXH2 2/20 0.52
▸ HTT P42858 1/20 0.52
▸ MAOA P21397 6/20 0.46
▸ MAOB P27338 6/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ GLA P06280 1/20 0.46
▸ MEN1 O00255 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ PDE10A Q9Y233 2/20 0.41
▸ GABRP O00591 2/20 0.39
▸ GABRD O14764 2/20 0.39
▸ GABRA1 P14867 2/20 0.39
▸ GABRB1 P18505 2/20 0.39
▸ GABRG2 P18507 2/20 0.39
▸ GABRB3 P28472 2/20 0.39
▸ GABRA5 P31644 2/20 0.39
▸ GABRA3 P34903 2/20 0.39
▸ GABRA2 P47869 2/20 0.39
▸ GABRB2 P47870 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31231900 0.85 PTPN1 (0.50) PTPN1KDM4EHTTMAOAMAOB
SCHEMBL23330765 0.85 PTPN1 (0.50) PTPN1KDM4EHTTMAOAMAOB
SCHEMBL28990316 0.81 PTPN1 (0.65) PTPN1KDM4EHTTMAOAMAOB
SCHEMBL9056199 0.79 ALDH1A1 (0.55) MAOAMAOBALDH1A1RAB9A
SCHEMBL27700648 0.79 PTPN1 (0.61) PTPN1KDM4EHTTMAOAMAOB
SCHEMBL20172523 0.79 PTPN1 (0.61) PTPN1KDM4EHTTMAOAMAOB
SCHEMBL14384453 0.79 PTPN1 (0.61) PTPN1KDM4EHTTMAOAMAOB
SCHEMBL13978663 0.76 PTPN1 (1.00) PTPN1KDM4EHTTMAOAMAOB
SCHEMBL29951299 0.76 PTPN1 (1.00) PTPN1KDM4EHTTMAOAMAOB
SCHEMBL11618900 0.75 MAOB (0.63) PTPN1KDM4EHTTMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103275052-A Method for synthesizing isoflavone by nickel-catalyzed Negishi cross coupling reaction at room temperature UNIV SHAANXI NORMAL 2013-09-04 — — CN disclosed
US-20080300298-A1 Honokiol Derivates For the Treatment of Proliferative Disorders NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-04 — — US disclosed
US-20080300298-A1 Honokiol Derivates For the Treatment of Proliferative Disorders NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-12-04 — — US disclosed
WO-1996012718-A1 NOUVELLES 2-[1-(φ-PHENOXYALCOYLPIPERIDIN-4-YL)AMINOMETHYLENE]-2H-BENZOFURAN-3-ONES SUBSTITUEES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE PIERRE FABRE MEDICAMENT (FR) 1996-05-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300298-A1 Honokiol Derivates For the Treatment of Proliferative Disorders CCNK, CDK3, CCNO PTPN1 3779/4885KDM4E 2859/4885HTT 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.